Persistence and adherence to rivastigmine in patients with dementia

Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan

Chee Jen Chang, Tse Chih Chou, Chiung Chih Chang, Ta Fu Chen, Chaur Jong Hu, Jong Ling Fuh, Wenfu Wang, Chiung Mei Chen, Winco Hsu, Chin Chang Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. Results: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. Discussion: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume5
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Rivastigmine
National Health Programs
Taiwan
Dementia
Retrospective Studies
Databases
Research
Patient Compliance

Keywords

  • Adherence
  • Donepezil
  • National Health Insurance Research Database
  • Persistence
  • Rivastigmine

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

@article{2645e62acc9842d7a1d9ee587e16fb0f,
title = "Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan",
abstract = "Introduction: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. Results: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. Discussion: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined.",
keywords = "Adherence, Donepezil, National Health Insurance Research Database, Persistence, Rivastigmine",
author = "Chang, {Chee Jen} and Chou, {Tse Chih} and Chang, {Chiung Chih} and Chen, {Ta Fu} and Hu, {Chaur Jong} and Fuh, {Jong Ling} and Wenfu Wang and Chen, {Chiung Mei} and Winco Hsu and Huang, {Chin Chang}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.trci.2018.06.013",
language = "English",
volume = "5",
pages = "46--51",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Persistence and adherence to rivastigmine in patients with dementia

T2 - Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan

AU - Chang, Chee Jen

AU - Chou, Tse Chih

AU - Chang, Chiung Chih

AU - Chen, Ta Fu

AU - Hu, Chaur Jong

AU - Fuh, Jong Ling

AU - Wang, Wenfu

AU - Chen, Chiung Mei

AU - Hsu, Winco

AU - Huang, Chin Chang

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. Results: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. Discussion: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined.

AB - Introduction: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. Results: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. Discussion: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined.

KW - Adherence

KW - Donepezil

KW - National Health Insurance Research Database

KW - Persistence

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=85060751501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060751501&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2018.06.013

DO - 10.1016/j.trci.2018.06.013

M3 - Article

VL - 5

SP - 46

EP - 51

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

ER -